Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Optimizing Adjuvant Endocrine Therapy: Where Do We Stand in 2008?

Release Date: August 22, 2008| Expiration Date: September 10, 2009
Jul 23, 2008, Koloa, HI

Lecture Overview

This activity will update physicians on the latest clinical data concerning the selection of adjuvant endocrine therapy regimens for pre- and post-menopausal patients with hormone receptor-positive early-stage breast cancer. This educational activity is directed toward medical, radiation, and surgical oncologists with an interest in the treatment of breast cancer. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity. Fellows, oncology nurses, oncology physician assistants, and pharmacists who are interested in the treatment of breast cancer are also invited to participate. At the conclusion of this activity, you should be able to:

• Assess the ongoing risk of recurrence for patients with hormone receptor–positive breast cancer and the implications for adjuvant endocrine therapy strategies

• Compare the efficacy/safety of up-front aromatase inhibitor therapy to that of tamoxifen/aromatase inhibitor switching or sequencing strategies in the adjuvant setting

• Discuss the effects of polymorphisms in CYP2D6 or other metabolic enzymes and of drugs that inhibit CYP2D6 activity on tamoxifen metabolism and their implications for treatment decisions for patients with hormone receptor–positive breast cancer

• Discuss the rationale for extended adjuvant endocrine therapy and recent data from trials investigating different durations of therapy

Instructions for Participation

  1. Read the following information before beginning the educational activity.
  2. Complete the CME pre-test.
  3. View and study all Flash video presentations.
  4. Complete the CME test.
  5. Answer the evaluation questions.
  • CME credit will be granted for online participation only.

Read all of the conditions in the Activity Terms box below. You must accept the Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians' Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians' Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians' Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from Optimizing Adjuvant Endocrine Therapy: Where Do We Stand in 2008? symposium have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Nancy Davidson, MD
Research Funding – Eisai Medical Research Inc

Eric P. Winer, MD
No relevant financial relationships to disclose

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users
Compatible Web browsers include

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the faculty and Physicians' Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy

Physicians' Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2008 by Physicians' Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Optimizing Adjuvant Endocrine Therapy: Where Do We Stand in 2008?
Physicians' Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3456
Fax: (214) 367-3304
E-mail: editor@pergrouplp.com

Educational Grants

An educational grant for this activity was provided by:


  1. Novartis Oncology